Glaucoma, Intraocular Pressure
Conditions
Keywords
Refractory glaucoma, Transcleral cyclophotocoagulation (TSCPC), Dark iris, Pops-titration, Slow-coagulation, Neovascular glaucoma
Brief summary
* Transcleral cyclophotocoagulation (TSCPC) has long been used as refractory glaucoma management and is very easy to learn and easy to perform. * Recent advances in laser technology; the role of TSCPC is being expanded because it has benefits of noninvasive glaucoma procedure. * The titration (pops), the fixed high-energy, and the fixed-low energy (slow-coagulation) are three energy delivery techniques. * The present study would report on the outcome (efficacy and safety) of the slow-coagulation versus the titration method in treatment of refractory glaucoma with dark iris. * The results would provide reliable evidences to supplement clinical judgment when making a decision in favor of each treatment method for glaucoma patients.
Detailed description
* Several protocols afford delivery of the optimum dose of laser energy per session necessary to achieve a long-term effective ocular hypotensive response balancing risks related to a high energy treatment and risks related to retreatment due to suboptimum dose delivery. * There are two main approaches to delivering laser energy, the pops-titration method and the fixed energy method that are the fixed-high and low-energy (the Gaasterland's slow-coagulation technique). * Of particular interest is which laser energy delivery method (slow-coagulation versus pops-titration) affords the optimal dose of photocoagulation necessary to achieve an effective long-term intraocular pressure (IOP) reduction while minimizing the risk of adverse events related to overtreatment and retreatments especially in refractory glaucomatous eyes with dark iris color.
Interventions
PROCEDUREThe pops-titration group
The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
PROCEDUREThe slow-coagulation group
The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
Sponsors
Prince of Songkla University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Refractory glaucoma (Neovascular glaucoma) with * Eyes with no visual potential and very high intraocular pressure (on maximal medical treatment) in which the intraocular pressure will probably cause corneal complications * Eyes with no visual potential and very high intraocular pressure (on maximal medical treatment) in which the intraocular pressure cause eye pain and need pain relief * Eyes with minimal useful vision and intraocular pressure over the target intraocular pressure * Eyes in which trabeculectomy with mitomycin-C and/or drainage implants have a high probability of failure * Eyes in which trabeculectomy with mitomycin-C and/or drainage implants have previously failed * Patient refuses to undergo more aggressive intraocular surgery * Patients whose general medical condition precludes invasive surgery
Exclusion criteria
* The visual acuity in the fellow eye is no light perception * Have previously been treated by the transcleral cyclophotocoagulation * Allergy to anesthetic medication * Can not measure the intraocular pressure by the applanation method
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success rate | 60 months | Success rate defined as the proportion of eyes achieving an intraocular pressure between 6 and 21mmHg with or without topical antiglaucoma medication at the final follow up visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 60 months | Response rate defined as the proportion of eyes achieving an intraocular pressure between \< 22 mmHg or \> 30% drop in an intraocular pressure with or without topical antiglaucoma medication at the final follow up visit. |
| Cyclodiode efficacy index | 60 months | Cyclodiode efficacy index defined as the ratio of response rate to the mean number of the treatment session. |
| Failure rate | 60 months | Failure rate defined as the proportion of eyes developed hypotony or phthisis bulbi or need to repeat treatment for more than 2 laser sessions. |
Countries
Thailand
Outcome results
None listed